ClinicalTrials.gg
Not yet recruitingNCT07470775DEX-SNS-SEPSISUpdated Mar 13, 2026

Early Dexmedetomidine and Sympathetic Regulation in Sepsis

A Phase 4 interventional study of Dexmedetomidine (DEX) and Placebo in Sepsis and Septic Shock, sponsored by Sichuan Academy of Medical Sciences. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-13.

Primary conditionShock, SepticRegistry: SepsisReclassifiedWhy we changed it
Registry
Sepsis — the first condition term the registry derived for this study.
ClinicalTrials.gg
Shock, Septic
Why
  1. The study's listed conditions name Shock, Septic, a narrower term within Sepsis.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Sichuan Academy of Medical Sciences · Phase 4, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
168
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 11 studies testing dexmedetomidine in Shock, Septic — 4 open to participants now, 4 under way, 1 of them phase 3. Dexmedetomidine · Shock, Septic.

Planned enrollment
2nd of 11
168 · median 40
Started
2026
with 2 others
Phase 4
3 of 11
2 open now
Registered
9th of 11
by date
Lead sponsor
1 of 11
Sichuan Academy of Medical Sciences

Among the 11 studies testing dexmedetomidine in Shock, Septic, this one is the 2nd largest by planned enrollment, is one of 3 that started in 2026, is one of 3 in phase 4, and was the 9th registered.

Shock, Septic

1,084 studies on the registry are indexed under Shock, Septic; 236 are open to participants now.

Browse Shock, Septic studies →

Open to participants now

4 of the 11 studies testing dexmedetomidine in Shock, Septic are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

About dexmedetomidine

Dexmedetomidine: first FDA approval 1999 (PRECEDEX), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 137 Shock, Septic studies recruiting now, 103 (75%) set no upper age limit and 18 (13%) stop at 75 or younger; 11 take children under 18; 14 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies testing dexmedetomidine in Shock, Septic, or all of them as a file.
02

Study summary

The goal of this clinical trial is to learn whether early administration of dexmedetomidine can improve autonomic nervous system regulation and clinical outcomes in adult patients with septic shock. It will also evaluate the safety of dexmedetomidine in this population.

The main questions it aims to answer are:

Does early dexmedetomidine improve sympathetic nervous system activity, as measured by heart rate variability (HRV) and blood pressure variability (BPV)?

Does dexmedetomidine reduce endogenous catecholamine levels and vasopressor requirements?

Does early autonomic modulation improve organ function and survival outcomes in septic shock? Researchers will compare dexmedetomidine to a placebo (normal saline) to determine whether dexmedetomidine improves hemodynamic stability and prognosis in patients with septic shock.

Participants will:

Be randomly assigned to receive dexmedetomidine (0.5 μg/kg/h) or placebo by continuous intravenous infusion for 48 hours

Undergo continuous ECG and invasive blood pressure monitoring

Have blood samples collected at predefined time points to measure inflammatory markers and endogenous catecholamine levels

Be assessed for organ function, vasopressor use, and perfusion parameters during the first 48 hours

Be followed up for 28-day and 90-day survival outcomes

03

Conditions studied

  • Sepsis
  • Septic Shock

Browse trials for

Keywords

  • Dexmedetomidine
  • Sympathetic Nervous System
  • Septic Shock
04

In context

Shock, Septic Reclassified

1,084 studies on the registry are indexed under Shock, Septic; 236 are open to participants now.

This study's planned enrollment of 168 is above the median of 78 across 639 interventional studies indexed under Shock, Septic.

Browse Shock, Septic studies →

Lead sponsor

Sichuan Academy of Medical Sciences is the lead sponsor of 18 studies on the registry; 11 are open to participants now.

Compared within Shock, Septic, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Sepsis. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Age ≥ 18 year Septic shock defined by Sepsis-3 criteria Enrollment within 24 hours of diagnosis APACHE II score > 10

Exclusion criteria

Exclusion Criteria:

Pregnancy or lactation Second- or third-degree atrioventricular block Persistent bradycardia (HR \<50 bpm) requiring intervention to dexmedetomidine Norepinephrine dose >0.5 μg/kg/min End-stage disease or \<72 hours Any condition deemed unsuitable by the investigator

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

06

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
168 participants (estimated)

Study arms

  • Placebo comparator
    ARM1

    Drug: Placebo

  • Active comparator
    Dexmedetomidine

    Drug: Dexmedetomidine (DEX)

Interventions

07

What researchers measure

Primary outcomes

  1. Heart Rate Variability (HRV)

    Heart rate variability will be assessed using continuous electrocardiographic monitoring. The primary HRV parameter analyzed will be the standard deviation of normal-to-normal intervals (SDNN).

    Time frame: From enrollment to the end of treatment at 48 hours

Secondary outcomes

  1. Change in Sequential Organ Failure Assessment (SOFA) Score

    The change in Sequential Organ Failure Assessment (SOFA) score from baseline to 48 hours will be used to evaluate organ dysfunction.

    Time frame: From enrollment to the end of treatment at 48 hours

  2. Interleukin-6 (IL-6) level

    Change in plasma IL-6 levels from baseline to 48 hours

    Time frame: From enrollment to the end of treatment at 48 hours

  3. ICU length of stay

    Duration of ICU stay for each participant

    Time frame: From enrollment to ICU discharge or 90 days, whichever occurs first

  4. Duration of Mechanical Ventilation

    Total duration of invasive mechanical ventilation during the first 48 hours after enrollment.

    Time frame: From randomization until successful liberation from mechanical ventilation, assessed up to 28 days.

  5. Requirement for Renal Replacement Therapy (RRT)

    Number of participants requiring renal replacement therapy during the first 48 hours after enrollment.

    Time frame: From randomization to 28 days after randomization.

  6. Tumor necrosis factor-α (TNF-α) level

    Change in plasma TNF-α levels from baseline to 48 hours

    Time frame: From enrollment to the end of treatment at 48 hours

  7. Procalcitonin (PCT) clearance

    Percentage change in PCT levels relative to baseline

    Time frame: From enrollment to the end of treatment at 48 hours

  8. 28-day all-cause mortality

    Proportion of participants who die from any cause within 28 days of enrollment

    Time frame: From enrollment to 28 days

  9. 90-day all-cause mortality

    Proportion of participants who die from any cause within 90 days of enrollment

    Time frame: From enrollment to 90 days

  10. Incidence of new-onset organ dysfunction

    Number of participants developing new organ dysfunction during the study period

    Time frame: From enrollment to 90 days or ICU/hospital discharge, whichever occurs first

08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Kim D, Park Y, Choi KH, Park TK, Lee JM, Cho YH, Choi JO, Jeon ES, Yang JH. Prognostic Implication of RV Coupling to Pulmonary Circulation for Successful Weaning From Extracorporeal Membrane Oxygenation. JACC Cardiovasc Imaging. 2021 Aug;14(8):1523-1531. doi: 10.1016/j.jcmg.2021.02.018. Epub 2021 Apr 14. PubMed 33865793 ↗
  • Carrara M, Ferrario M, Bollen Pinto B, Herpain A. The autonomic nervous system in septic shock and its role as a future therapeutic target: a narrative review. Ann Intensive Care. 2021 May 17;11(1):80. doi: 10.1186/s13613-021-00869-7. PubMed 33999297 ↗
  • Haenecour AS, Seto W, Urbain CM, Stephens D, Laussen PC, Balit CR. Prolonged Dexmedetomidine Infusion and Drug Withdrawal In Critically Ill Children. J Pediatr Pharmacol Ther. 2017 Nov-Dec;22(6):453-460. doi: 10.5863/1551-6776-22.6.453. PubMed 29290746 ↗
  • Tobias JD. Dexmedetomidine: Are There Going to be Issues with Prolonged Administration? J Pediatr Pharmacol Ther. 2010 Jan;15(1):4-9. No abstract available. PubMed 22477787 ↗
  • Ammar MA, Sacha GL, Welch SC, Bass SN, Kane-Gill SL, Duggal A, Ammar AA. Sedation, Analgesia, and Paralysis in COVID-19 Patients in the Setting of Drug Shortages. J Intensive Care Med. 2021 Feb;36(2):157-174. doi: 10.1177/0885066620951426. Epub 2020 Aug 26. PubMed 32844730 ↗
  • Dargent A, Bourredjem A, Jacquier M, Bohe J, Argaud L, Levy B, Fournel I, Cransac A, Badie J, Quintin L, Quenot JP. Dexmedetomidine to Reduce Vasopressor Resistance in Refractory Septic Shock: alpha2 Agonist Dexmedetomidine for REfractory Septic Shock (ADRESS): A Double-Blind Randomized Controlled Pilot Trial. Crit Care Med. 2025 Apr 1;53(4):e884-e896. doi: 10.1097/CCM.0000000000006608. Epub 2025 Feb 28. PubMed 40019329 ↗
  • Shehabi Y, Howe BD, Bellomo R, Arabi YM, Bailey M, Bass FE, Bin Kadiman S, McArthur CJ, Murray L, Reade MC, Seppelt IM, Takala J, Wise MP, Webb SA; ANZICS Clinical Trials Group and the SPICE III Investigators. Early Sedation with Dexmedetomidine in Critically Ill Patients. N Engl J Med. 2019 Jun 27;380(26):2506-2517. doi: 10.1056/NEJMoa1904710. Epub 2019 May 19. PubMed 31112380 ↗
  • Grayson KE, Bailey M, Balachandran M, Banneheke PP, Belletti A, Bellomo R, Naorungroj T, Serpa-Neto A, Wright JD, Yanase F, Young PJ, Shehabi Y. The Effect of Early Sedation With Dexmedetomidine on Body Temperature in Critically Ill Patients. Crit Care Med. 2021 Jul 1;49(7):1118-1128. doi: 10.1097/CCM.0000000000004935. PubMed 33729724 ↗
  • Kurnik D, Friedman EA, Muszkat M, Sofowora GG, Xie HG, Dupont WD, Wood AJ, Stein CM. Genetic variants in the alpha2C-adrenoceptor and G-protein contribute to ethnic differences in cardiovascular stress responses. Pharmacogenet Genomics. 2008 Sep;18(9):743-50. doi: 10.1097/FPC.0b013e3282fee5a1. PubMed 18698227 ↗
  • Morelli A, Sanfilippo F, Arnemann P, Hessler M, Kampmeier TG, D'Egidio A, Orecchioni A, Santonocito C, Frati G, Greco E, Westphal M, Rehberg SW, Ertmer C. The Effect of Propofol and Dexmedetomidine Sedation on Norepinephrine Requirements in Septic Shock Patients: A Crossover Trial. Crit Care Med. 2019 Feb;47(2):e89-e95. doi: 10.1097/CCM.0000000000003520. PubMed 30394918 ↗
  • Dardalas I, Stamoula E, Rigopoulos P, Malliou F, Tsaousi G, Aidoni Z, Grosomanidis V, Milonas A, Papazisis G, Kouvelas D, Pourzitaki C. Dexmedetomidine effects in different experimental sepsis in vivo models. Eur J Pharmacol. 2019 Aug 5;856:172401. doi: 10.1016/j.ejphar.2019.05.030. Epub 2019 May 17. PubMed 31108055 ↗
  • Taniguchi T, Kidani Y, Kanakura H, Takemoto Y, Yamamoto K. Effects of dexmedetomidine on mortality rate and inflammatory responses to endotoxin-induced shock in rats. Crit Care Med. 2004 Jun;32(6):1322-6. doi: 10.1097/01.ccm.0000128579.84228.2a. PubMed 15187514 ↗
  • Geloen A, Chapelier K, Cividjian A, Dantony E, Rabilloud M, May CN, Quintin L. Clonidine and dexmedetomidine increase the pressor response to norepinephrine in experimental sepsis: a pilot study. Crit Care Med. 2013 Dec;41(12):e431-8. doi: 10.1097/CCM.0b013e3182986248. PubMed 23963131 ↗
  • Ostrowski SR, Gaini S, Pedersen C, Johansson PI. Sympathoadrenal activation and endothelial damage in patients with varying degrees of acute infectious disease: an observational study. J Crit Care. 2015 Feb;30(1):90-6. doi: 10.1016/j.jcrc.2014.10.006. Epub 2014 Oct 8. PubMed 25457118 ↗
  • Stolk RF, van der Pasch E, Naumann F, Schouwstra J, Bressers S, van Herwaarden AE, Gerretsen J, Schambergen R, Ruth MM, van der Hoeven JG, van Leeuwen H, Pickkers P, Kox M. Norepinephrine Dysregulates the Immune Response and Compromises Host Defense during Sepsis. Am J Respir Crit Care Med. 2020 Sep 15;202(6):830-842. doi: 10.1164/rccm.202002-0339OC. PubMed 32520577 ↗
  • Chirinos JA, Sweitzer N. Ventricular-Arterial Coupling in Chronic Heart Failure. Card Fail Rev. 2017 Apr;3(1):12-18. doi: 10.15420/cfr.2017:4:2. PubMed 28785470 ↗
  • Carrara M, Herpain A, Baselli G, Ferrario M. Vascular Decoupling in Septic Shock: The Combined Role of Autonomic Nervous System, Arterial Stiffness, and Peripheral Vascular Tone. Front Physiol. 2020 Jul 7;11:594. doi: 10.3389/fphys.2020.00594. eCollection 2020. PubMed 32733257 ↗
  • Dunser MW, Hasibeder WR. Sympathetic overstimulation during critical illness: adverse effects of adrenergic stress. J Intensive Care Med. 2009 Sep-Oct;24(5):293-316. doi: 10.1177/0885066609340519. Epub 2009 Aug 23. PubMed 19703817 ↗
  • Vessman J, Hartvig P. Gas chromatography and electron capture detection of benzophenone formed by chromic acid oxidation. 4. Effects of ring substituents and chain length on benzophenone yield in some gem-diphenylsubstituted compounds. Acta Pharm Suec. 1971 May;8(2):105-12. No abstract available. PubMed 5561320 ↗
  • Miller G, Chretien L. [Gastric plasmocytoma]. Union Med Can. 1966 Jun;95(6):744-6. No abstract available. French. PubMed 5934857 ↗
  • Deutschman CS, Hellman J, Ferrer Roca R, De Backer D, Coopersmith CM; Research Committee of the Surviving Sepsis Campaign. The Surviving Sepsis Campaign: Basic/Translational Science Research Priorities. Crit Care Med. 2020 Aug;48(8):1217-1232. doi: 10.1097/CCM.0000000000004408. PubMed 32697495 ↗
  • Evans L, Rhodes A, Alhazzani W, Antonelli M, Coopersmith CM, French C, Machado FR, Mcintyre L, Ostermann M, Prescott HC, Schorr C, Simpson S, Wiersinga WJ, Alshamsi F, Angus DC, Arabi Y, Azevedo L, Beale R, Beilman G, Belley-Cote E, Burry L, Cecconi M, Centofanti J, Coz Yataco A, De Waele J, Dellinger RP, Doi K, Du B, Estenssoro E, Ferrer R, Gomersall C, Hodgson C, Hylander Moller M, Iwashyna T, Jacob S, Kleinpell R, Klompas M, Koh Y, Kumar A, Kwizera A, Lobo S, Masur H, McGloughlin S, Mehta S, Mehta Y, Mer M, Nunnally M, Oczkowski S, Osborn T, Papathanassoglou E, Perner A, Puskarich M, Roberts J, Schweickert W, Seckel M, Sevransky J, Sprung CL, Welte T, Zimmerman J, Levy M. Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock 2021. Crit Care Med. 2021 Nov 1;49(11):e1063-e1143. doi: 10.1097/CCM.0000000000005337. No abstract available. PubMed 34605781 ↗

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Mar 2026; primary completion for Mar 2028, 24 months later.

Of 39 non-industry phase 4 interventional studies under Shock, Septic, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 38. This study's planned 24 months is close to that.

Counting every sponsor, half of 40 studies reached it within 24 months; a quarter within 16 and three quarters within 38.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 5, 2026
First posted
Mar 13, 2026
StartEst.
Mar 1, 2026
Primary completionEst.
Mar 1, 2028
CompletionEst.
Mar 1, 2028
Last update
Mar 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT07470775
Lead sponsor
Sichuan Academy of Medical Sciences
Responsible party
Rongan Liu (Associate Chief Physician, Intensive Care Unit, Sichuan Academy of Medical Sciences) — Principal investigator
First posted
Mar 13, 2026
Start date
Mar 1, 2026 (estimated)
Primary completion
Mar 1, 2028 (estimated)
Completion
Mar 1, 2028 (estimated)
Last update
Mar 13, 2026

Study contacts

rongan Liu
Contact
35279240@qq.com
+8615928731511

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dexmedetomidine

Start the discussion